產(chǎn)品名稱(chēng) |
COLO 829 |
商品貨號(hào) |
B164286 |
Organism |
Homo sapiens, human |
Tissue |
skin |
Cell Type |
fibroblast |
Product Format |
frozen |
Morphology |
fibroblast |
Culture Properties |
adherent |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
Melanoma |
Age |
45 years |
Gender |
male |
Ethnicity |
Caucasian |
Storage Conditions |
liquid nitrogen vapor phase |
Derivation |
The COLO 829 cell line was established by G.E. Moore from a biopsy specimen taken from a patient prior to chemotherapy for metastatic melanoma.
|
Clinical Data |
45 years Caucasian male |
Comments |
A cell line was also produced from peripheral blood B cells, and is available as COLO 829BL (ATCC CRL-1980)
Early passages of COLO 829 still contain a small percentage of melanin producing cells. |
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
Subculturing |
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 mL of Trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended Medium Renewal: 2 to 3 times per week |
Cryopreservation |
culture medium 95%; DMSO, 5% |
Culture Conditions |
Temperature: 37°C |
STR Profile |
Amelogenin: X CSF1PO: 11 D13S317: 11,12 D16S539: 13 D5S818: 11 D7S820: 8,10 THO1: 10 TPOX: 8,11 vWA: 17,19 |
Name of Depositor |
GE Moore |
Deposited As |
Homo sapiens |
Passage History |
Early passages of COLO 829 still contain a small percentage of melanin producing cells. |